Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN 
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Acurx Pharmaceuticals (ACXP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and Chief Financial Officer David Luci - President and Chief Executive Officer Conference Call Participants Thomas Yip - H.C. Wainwright James Molloy - Alliance Global Partners Claire Acheson - Independent Investment Research Operator Greetings and welcome to the Acurx Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results and Business Update.
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 28 to January 30, 2025 at the Borgata Hotel, Atlantic City, New Jersey.
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now
Acurx Pharmaceuticals (ACXP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, Corporate Secretary & Director Conference Call Participants Thomas Yip - H.C. Wainwright John Stinson - Private Investor Operator Greetings, and welcome to the Acurx Pharmaceuticals, Inc. Third Quarter 2024 Results and Business Update Conference Call.
Acurx Ready To Expand Pipeline With Anthrax Treatment
Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat, targeting C. difficile infections, a billion-dollar opportunity. Ibezapolstat's Phase 2 trials showed a 96% cure rate, positioning it as a potential game-changer with no preexisting resistance and minimal microbiome impact. The company's second asset showed activity against drug-resistant anthrax, making it a possible candidate for government funding.
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support
The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign. NEW YORK, NY / ACCESSWIRE / October 14, 2024 / New to The Street, one of the leading U.S. business television platforms, is pleased to announce the renewal of its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a late-stage biopharmaceutical company.
